vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and MID PENN BANCORP INC (MPB). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $62.0M, roughly 1.3× MID PENN BANCORP INC). MID PENN BANCORP INC runs the higher net margin — 31.4% vs -9.6%, a 41.0% gap on every dollar of revenue. On growth, MID PENN BANCORP INC posted the faster year-over-year revenue change (30.8% vs -16.8%). Over the past eight quarters, MID PENN BANCORP INC's revenue compounded faster (21.1% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Commerce Bancorp was a Cherry Hill, New Jersey–based bank created in 1973. In 2007, it was purchased by Toronto-Dominion Bank, which merged Commerce into TD Banknorth, the latter of which was rebranded to TD Bank.

BIOX vs MPB — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.3× larger
BIOX
$77.6M
$62.0M
MPB
Growing faster (revenue YoY)
MPB
MPB
+47.6% gap
MPB
30.8%
-16.8%
BIOX
Higher net margin
MPB
MPB
41.0% more per $
MPB
31.4%
-9.6%
BIOX
Faster 2-yr revenue CAGR
MPB
MPB
Annualised
MPB
21.1%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
MPB
MPB
Revenue
$77.6M
$62.0M
Net Profit
$-7.4M
$19.4M
Gross Margin
46.8%
Operating Margin
9.3%
43.6%
Net Margin
-9.6%
31.4%
Revenue YoY
-16.8%
30.8%
Net Profit YoY
-20.2%
47.0%
EPS (diluted)
$-0.12
$0.83

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
MPB
MPB
Q4 25
$62.0M
Q3 25
$77.6M
$61.8M
Q2 25
$54.3M
Q1 25
$60.6M
$47.7M
Q4 24
$98.8M
$47.4M
Q3 24
$93.3M
$45.3M
Q2 24
$44.1M
Q1 24
$84.0M
$42.3M
Net Profit
BIOX
BIOX
MPB
MPB
Q4 25
$19.4M
Q3 25
$-7.4M
$18.3M
Q2 25
$4.8M
Q1 25
$-1.6M
$13.7M
Q4 24
$605.2K
$13.2M
Q3 24
$-6.2M
$12.3M
Q2 24
$11.8M
Q1 24
$9.8M
$12.1M
Gross Margin
BIOX
BIOX
MPB
MPB
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
MPB
MPB
Q4 25
43.6%
Q3 25
9.3%
39.3%
Q2 25
7.9%
Q1 25
1.5%
35.2%
Q4 24
14.5%
34.1%
Q3 24
2.5%
32.8%
Q2 24
32.4%
Q1 24
15.7%
34.8%
Net Margin
BIOX
BIOX
MPB
MPB
Q4 25
31.4%
Q3 25
-9.6%
29.6%
Q2 25
8.8%
Q1 25
-2.6%
28.8%
Q4 24
0.6%
27.9%
Q3 24
-6.6%
27.1%
Q2 24
26.7%
Q1 24
11.6%
28.7%
EPS (diluted)
BIOX
BIOX
MPB
MPB
Q4 25
$0.83
Q3 25
$-0.12
$0.79
Q2 25
$0.22
Q1 25
$-0.02
$0.71
Q4 24
$0.00
$0.72
Q3 24
$-0.10
$0.74
Q2 24
$0.71
Q1 24
$0.14
$0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
MPB
MPB
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$814.1M
Total Assets
$734.9M
$6.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
MPB
MPB
Q4 25
Q3 25
$15.5M
Q2 25
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
Q1 24
$16.4M
Stockholders' Equity
BIOX
BIOX
MPB
MPB
Q4 25
$814.1M
Q3 25
$288.3M
$796.3M
Q2 25
$775.7M
Q1 25
$345.0M
$667.9M
Q4 24
$346.3M
$655.0M
Q3 24
$346.0M
$573.1M
Q2 24
$559.7M
Q1 24
$348.5M
$551.0M
Total Assets
BIOX
BIOX
MPB
MPB
Q4 25
$6.1B
Q3 25
$734.9M
$6.3B
Q2 25
$6.4B
Q1 25
$798.2M
$5.5B
Q4 24
$835.2M
$5.5B
Q3 24
$827.3M
$5.5B
Q2 24
$5.4B
Q1 24
$836.1M
$5.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
MPB
MPB
Operating Cash FlowLast quarter
$14.4M
$80.0M
Free Cash FlowOCF − Capex
$71.8M
FCF MarginFCF / Revenue
115.8%
Capex IntensityCapex / Revenue
13.3%
Cash ConversionOCF / Net Profit
4.12×
TTM Free Cash FlowTrailing 4 quarters
$132.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
MPB
MPB
Q4 25
$80.0M
Q3 25
$14.4M
$26.3M
Q2 25
$29.0M
Q1 25
$23.3M
$11.5M
Q4 24
$-5.4M
$51.4M
Q3 24
$5.2M
$16.9M
Q2 24
$18.0M
Q1 24
$-17.4M
$12.4M
Free Cash Flow
BIOX
BIOX
MPB
MPB
Q4 25
$71.8M
Q3 25
$24.3M
Q2 25
$27.2M
Q1 25
$8.8M
Q4 24
$44.5M
Q3 24
$16.8M
Q2 24
$17.7M
Q1 24
$12.1M
FCF Margin
BIOX
BIOX
MPB
MPB
Q4 25
115.8%
Q3 25
39.4%
Q2 25
50.1%
Q1 25
18.4%
Q4 24
93.8%
Q3 24
37.1%
Q2 24
40.2%
Q1 24
28.5%
Capex Intensity
BIOX
BIOX
MPB
MPB
Q4 25
13.3%
Q3 25
3.1%
Q2 25
3.2%
Q1 25
5.7%
Q4 24
14.6%
Q3 24
0.0%
Q2 24
0.7%
Q1 24
0.8%
Cash Conversion
BIOX
BIOX
MPB
MPB
Q4 25
4.12×
Q3 25
1.44×
Q2 25
6.08×
Q1 25
0.84×
Q4 24
-8.85×
3.88×
Q3 24
1.37×
Q2 24
1.53×
Q1 24
-1.78×
1.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons